Valuation: Protalix BioTherapeutics, Inc.

Market Cap 185M 0 162M 149M 139M 263M 17.59B 267M 1.79B 697M 8.68B 696M 681M 30B P/E 2026 *
11.8x
P/E 2027 * 46x
Enterprise Value 185M 0 162M 149M 139M 263M 17.59B 267M 1.79B 697M 8.68B 696M 681M 30B EV / Sales 2026 *
2.37x
EV / Sales 2027 * 2.74x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2019-06-29
Director of Finance/CFO 58 2025-08-23
Chief Tech/Sci/R&D Officer - 2024-05-31
Director TitleAgeSince
Director/Board Member 73 2008-06-30
Director/Board Member 82 2014-10-31
Director/Board Member 58 2019-06-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 185M
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
+2.14%-2.07%+27.62%+22.57% 328B
+1.87%+1.87%+40.58%+42.08% 292B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
Average +1.97%+0.98%+31.96%+61.73% 402.71B
Weighted average by Cap. +2.39%+0.70%+43.48%+88.16%

Financials

2026 *2027 *
Net sales 78.3M 0 68.52M 63.15M 58.53M 111M 7.43B 113M 757M 294M 3.67B 294M 288M 12.68B 67.56M 0 59.13M 54.49M 50.51M 95.88M 6.41B 97.42M 653M 254M 3.16B 254M 248M 10.94B
Net income 15.72M 0 13.76M 12.68M 11.75M 22.31M 1.49B 22.67M 152M 59.13M 736M 59.03M 57.75M 2.55B 4.07M 0 3.56M 3.29M 3.05M 5.78M 387M 5.87M 39.39M 15.32M 191M 15.29M 14.96M 659M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.300USD
Average target price
11.00USD
Spread / Average Target
+378.26%

Quarterly revenue - Rate of surprise